+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chromatin Readers in Health and Disease. Translational Epigenetics Volume 35

  • Book
  • October 2022
  • Elsevier Science and Technology
  • ID: 5527258
Chromatin Readers in Health and Disease, Volume 32, a new release in the Translational Epigenetics series, gathers and makes actionable our current understanding of how chromatin readers regulate access to genetic information, and how their aberrant regulation can contribute to human pathologies. Chromatin readers discussed include 14-3-3 Dinshaw, ADD, Ankyrin, BAH, BET, BIR, BRCT, bromodomains and Kac readers, chromodomains and chromobarrel readers, citrullination readers, macrodomains and poly-ADP-ribose readers, MBT, PHD and double PHD, PWWP, SUMO (H4K12) readers, Tudor and TTD, UDR and ubiquitin, WD40, YEATS (crotonyl reader)?, MBD, SRA, and Methyl-RNA readers.

In the book, more than a dozen leaders in the field examine a range of protein readers, their relationship to human disease, and the early therapeutics that act as chromatin signaling factors to treat cancers and Huntington's disease, among other disorders.

Table of Contents

1. ADD domains a regulatory hub in chromatin biology and disease
2. BAH
3. BIR
4. BRCT Domains as Chromatin Readers: Structure, Function, and Clinical Implications
5. The bromodomain acyl-lysine readers in human health and disease
6. Chromodomains
7. CW-type zinc fingers
8. Macrodomains and PAR readers
9. MBT
10. PHD and double PHD finger
11. PWWP
12. SPIN repeats and human pathologies
13. Tudor and TTD
14. UDR and Ubiquitin
15. WD40
17. Multivalent readers and interplay among different readers
18. DNA Methylation and Reader- or Writer-Proteins: Differentiation and Disease
19. R-loops readers
20. CUT&RUN and CUT&Tag: Low-input methods for genome-wide mapping of chromatin proteins


Olivier Binda Principal Investigator, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK. Dr. Olivier Binda is a Principal Investigator at Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, England, specializing in epigenetics and gene expression as it relates to human disease. Dr. Binda co-edited Chromatin Signaling and Diseases (Elsevier 2016), a volume in Elsevier's Translational Epigenetics series, and has published 20 scientific papers in such peer reviewed journals as the Journal of Biological Chemistry, Biochemistry, Epigenetics, Oncogene, Scientific Reports, and Stem Cell Research. In past positions he has served as a postdoctoral fellow at McGill University and Stanford University, and he completed his PhD in Biochemistry at McGill University in 2007.